The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?

Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.

Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.

Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

Meanwhile, Bristol’s other competition in this disease looks set to come from China.

Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.

Meanwhile, Lilly gets in on the next-gen KRAS action.

But the group’s attempt to join Janux at the high altar of masking technology falls flat.